WO2013114358A1 - Negatively charged vascular stent - Google Patents
Negatively charged vascular stent Download PDFInfo
- Publication number
- WO2013114358A1 WO2013114358A1 PCT/IL2013/050074 IL2013050074W WO2013114358A1 WO 2013114358 A1 WO2013114358 A1 WO 2013114358A1 IL 2013050074 W IL2013050074 W IL 2013050074W WO 2013114358 A1 WO2013114358 A1 WO 2013114358A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- coating
- stent
- article
- needle
- wire
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/82—Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/86—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure
- A61F2/90—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/28—Materials for coating prostheses
- A61L27/30—Inorganic materials
- A61L27/306—Other specific inorganic materials not covered by A61L27/303 - A61L27/32
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/28—Materials for coating prostheses
- A61L27/34—Macromolecular materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/08—Materials for coatings
- A61L31/082—Inorganic materials
- A61L31/088—Other specific inorganic materials not covered by A61L31/084 or A61L31/086
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/08—Materials for coatings
- A61L31/10—Macromolecular materials
-
- C—CHEMISTRY; METALLURGY
- C23—COATING METALLIC MATERIAL; COATING MATERIAL WITH METALLIC MATERIAL; CHEMICAL SURFACE TREATMENT; DIFFUSION TREATMENT OF METALLIC MATERIAL; COATING BY VACUUM EVAPORATION, BY SPUTTERING, BY ION IMPLANTATION OR BY CHEMICAL VAPOUR DEPOSITION, IN GENERAL; INHIBITING CORROSION OF METALLIC MATERIAL OR INCRUSTATION IN GENERAL
- C23C—COATING METALLIC MATERIAL; COATING MATERIAL WITH METALLIC MATERIAL; SURFACE TREATMENT OF METALLIC MATERIAL BY DIFFUSION INTO THE SURFACE, BY CHEMICAL CONVERSION OR SUBSTITUTION; COATING BY VACUUM EVAPORATION, BY SPUTTERING, BY ION IMPLANTATION OR BY CHEMICAL VAPOUR DEPOSITION, IN GENERAL
- C23C14/00—Coating by vacuum evaporation, by sputtering or by ion implantation of the coating forming material
- C23C14/22—Coating by vacuum evaporation, by sputtering or by ion implantation of the coating forming material characterised by the process of coating
- C23C14/34—Sputtering
- C23C14/3407—Cathode assembly for sputtering apparatus, e.g. Target
- C23C14/3414—Metallurgical or chemical aspects of target preparation, e.g. casting, powder metallurgy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/82—Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2240/00—Manufacturing or designing of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2240/001—Designing or manufacturing processes
Definitions
- the invention relates to medical devices for mitigating thrombosis risk and more specifically to a stent carrying a stable negative charge.
- a stent is an artificial 'tube' inserted into a natural passage/conduit in the body to prevent, or counteract, a disease-induced, localized flow constriction.
- the stents are inserted into narrowed coronary arteries to help keep them open after balloon angioplasty. The stent then allows the normal flow of blood and oxygen to the heart. Stents placed in narrowed carotid arteries (the vessels in the front of the neck that supply blood to the brain) appear useful in treating patients at elevated risk for stroke.
- WO/1996/041589 discloses a device for implantation in a vessel or hollow organ lumen in a human or animal body, such as a self-expanding stent, a cava filter, an embolizing means or a supporting means, comprises a wire frame with a plurality of interconnected cells made of at least two separate wire sections which are intercrossing at cell junctions and form closed cells. At the cell junctions the wires are knot to form a geometrical locking of the cells so that the wire-shaped cell sides in respective cells are locked at the cell junctions when the wire frame is subjected to pressure acting radially inwards.
- RU 2446775 discloses a stent includes a tubular element which has longitudinal axis.
- Tubular element contains first radial element and second radial element.
- First radial element contains elongated bridge with deflectable teeth.
- Bridge is characterized by upper and lower parts. Upper part narrows from first thickness to second thickness on first direction on circumference, approaching far edge of upper part. Lower part narrows from first thickness to second thickness in direction on circumference opposite to first direction, approaching far edge of lower part.
- Second radial element is located on circumference near first radial element and contains gearing means, which have configuration for sliding gearing of elongated bridge of first radial element and deflection of deflectable teeth, when teeth contact with gearing means in such a way that tubular element reaches extension in direction on circumference with reduced kickback.
- Gearing means narrow to second thickness in direction on circumference, approaching far edge of gearing means.
- gearing means of second radial element include slot intended for sliding gearing of first radial element bridge and deflection of teeth, when elongated bridge of first radial element passes through slot, in such a way that tubular element obtains extension in direction on circumference with reduced kickback.
- Second radial element does not overlap itself when stent is in extended state.
- Gearing means narrow on circumference to second thickness, approaching far edge of gearing means in such a way, that first and second radial elements preserve mainly constant common thickness, when first radial element is geared by gearing means of second radial element and stent is in extended state.
- US 6231600 discloses a device such as a stent provided with a hybrid coating including a time released, restenosis inhibiting coating and a non-thrombogenic coating to prevent clotting on the device.
- One first coat or layer includes a polymer, a crosslinking agent, and pacitaxel, analogues, or derivatives thereof.
- the first coat preferably includes a polymer having Taxol admixed therein so as to be releasable over time.
- the first coat preferably includes a polyfunctional aziridine as the crosslinking agent.
- the second coat preferably includes heparin to inhibit clot formation on the device.
- the crosslinking agent can covalently bond to both the first coat polymer and the second coat heparin.
- a stent can be provided with a first coat including an aqueous dispersion or emulsion of a polymer and an excess of crosslinking agent.
- the first coating can be dried, leaving a water insoluble polymer coating.
- a second aqueous coating including a solution or dispersion of heparin can be applied over the first coating, the heparin becoming covalently bound to the crosslinking agent on the first coating surface.
- the resulting stent can inhibit restenosis while preventing blood clot formation on the stent.
- RU 2380059 discloses a stent coating containing a polymer material with an active antiproliferative substance.
- the polymer material presents a copolymer of butyric and valeric acids, while the active antiproliferative substance is rubomycinum.
- the amount of the copolymer of butyric and valeric acids per one stent is 2-15 mg/stent, while rubomycinum composes a polymer layer in amount 0.002-0.025 mg/stent.
- US Patent Application 2008/0208315 disclosed a stent for coronary vessels, having a surface of multilayer immobilized structures, includes a stent body and a number of polyelectrolyte complex (PEC) layers stacking and being immobilized on the surface of the stent body, in which the PEC layer is formed of a polymer layer and an anticoagulant layer.
- the coronary stent is capable of effectively improving the hemocompatibility and longevity over a conventional stent using surface encapsulation of an anticoagulant layer for hemocompatibility improvement.
- the coronary stent can be use as a drug-eluting coronary stent, thus allowing for the time-releasing of drugs, and further preventing the thickening of vascular smooth muscle cells for causing vascular thrombosis.
- the stent structure comprises a pair of coaxial metal stents having a layer of dielectric material between the stents.
- a battery is operatively connected preferably near or adjacent to the upstream end upon deployment of the stent.
- the positive battery terminal establishes an electrical connection to the outer metal stent and the negative terminal establishes an electrical connection to the inner metal stent and this exhibits a capacitor-like properties.
- the inner metal stent being negatively charged, promotes a platelet repellent, anti-thrombotic effect.
- US Patent Application 2011/0196478 discloses devices and methods for lumen treatment.
- an endoprosthesis that includes an internal layer designed to provide a negative electric field directed endoluminally; an external layer designed to provide a positive electric field directed exoluminally; and one or more intermediate layers disposed between the internal layer and the external layer, wherein the negative electric field is due to a negative point charge between about -25 mV and about -250 mV, and wherein the positive electric field is due to a positive point charge between about +1 mV and about +30 mV.
- vascular stents known in the art are characterized by substantive hydrophilicity. Thrombogenic blood particles freely penetrate into the gaps between stent elements or between the stent and vascular walls and aggregate into a new clot. The chances that surgically treated blood vessels will be re-stenosed are very good. Thus, there is a long- felt and unmet need to provide a hydrophobic vascular stent which is able to repel the aforesaid thrombogenic blood particles and prevents the surgically treated blood vessels from recurrent stenosis and sclerosis.
- Another object of the invention is to disclose the article selected from the group consisting of a vascular stent, an artificial cardiac valve, a suture material, orthopedic article, applicator, hernia mesh, acupuncture needle including corporeal needle, otic needle, long-term needle, ball, plate, and any combination thereof.
- Another object of the invention is to disclose a vascular stent carrying a negative charge.
- the aforesaid stent comprises at least one metal wire member configured into a cylindrical celled frame.
- a further object of the invention is to disclose the coating having an integral surface blanketing an entire surface of said wire member.
- a further object of the invention is to disclose the coating which is tantalum pentoxide.
- a further object of the invention is to disclose the tantalum pentoxide coating which is vacuum-plasma sputtering.
- a further object of the invention is to disclose the coating is Polytetrafluoroethylene.
- a further object of the invention is to disclose the vascular stent constructed of tubing cut into a mesh shape.
- a further object of the invention is to disclose the vascular stent constructed of at least one wire into a mesh shape.
- a further object of the invention is to disclose the stent in which a distance between each two neighboring wires of said stent is less 15 wire diameters such that said stent provides substantially uniform electrostatic field preventing blood cells from aggregation on the stent wires.
- a further object of the invention is to disclose a method of manufacturing a vascular stent carrying a negative charge and insertable into a patient's body.
- the aforesaid method comprises the steps of: (a) providing an article work piece; and (b) coating said wire members with a coating carrying a negative charge; and
- It is another core purpose of the invention to provide the step of coating article work piece further comprises creating an electret structure of said work piece.
- a further object of the invention is to disclose the step of coating said wire members further comprising creating an integral surface blanketing an entire surface of said wire member.
- a further object of the invention is to disclose the step of coating said wire members further comprising sputtering tantalum pentoxide.
- a further object of the invention is to disclose the step of sputtering tantalum pentoxide which is performed by means of vacuum-plasma sputtering.
- Figs la and lb are general views of a wire wound stents
- Fig. lc is a general view of a stent braided of a wire
- Fig. Id is a general view of a stent cut of a tube by a laser
- Fig. 2a is an exemplar view of a mesh structure which is cut by a laser
- Fig. 2b is an exemplar view of a mesh structure formed of wavelike wires
- Fig. 2c is an exemplar view of a mesh structure formed of interlaced wires
- Fig. 3a is an illustration specifying aggregation of blood particles into a clot
- Fig. 3b is an illustration specifying prevention of blood particles from aggregation into a clot.
- the core objective of the present invention is to reduce the risk of recurrent thrombosis.
- the vascular stent of the present invention is characterized high biological compatibility including hemocompatibility and temporally stable anti-coagulating and anti-clotting properties implantable into coronary or other arteries to restore patency thereof.
- a vascular stent constituting a cylindrical celled frame made of at least one wire member is coated with a coating having an electret structure.
- the aforesaid coating carries negative surface charge.
- the electret coating has an integral surface blanketing an entire surface of the stent. In other words, there is a negative potential on entire surface of the stent.
- the electret structure is formed by means of coating the stent with tantalum pentoxide (Ta 2 Os).
- the electret coating is made of polytetrafluoroethylene (Teflon ® ). Negative charge carried by the vascular stent coated with electret films prevents blood plates such as thrombocytes or leucocytes from aggregation at a stent mounted within a blood vessel. It is known that the blood cells to be aggregated at the stent are negatively charged.
- Electronegativity of the stent surface results in prevention of blood cell aggregation both at the stent per se and the vascular wall-adjacent area due to repelling Coulomb forces.
- the negative surface charge generates electric static field shielding areas potentially prone to blood cell aggregation.
- the vascular stent carrying the electret coating decreases risk of restenosis. Life quality and longevity of the patients stented with temporally stable anti-coagulating and anti-clotting properties are improved in comparison with the unstented patient. Doses of anti-coagulating and anti-clotting medicine are cut as well.
- the stent is expanded due to plastic deformation when mounted within the blood vessel, for example, by means of an inflatable balloon.
- At least one wire member is configured into a cylindrical celled structure.
- the aforesaid wire member is coated with tantalum pentoxide.
- the tantalum pentoxide coating is made by means of vacuum-plasma sputtering.
- the wire member is coated with Polytetrafluoroethylene.
- the stents provided with tantalum coating are characterized by higher reagent resistance in comparison with the gold coated stents. Tantalum pentoxide is dielectric and characterized by high mechanical properties. Tantalum pentoxide is chemically inert and biologically compatible. Thus, the stent provided with tantalum pentoxide coating is safely implantable into blood vessel and may reside in situ for a long time without expected side effects such as toxicity from stent degradation products and repeat thrombosis at the stent.
- Tantalum oxide coating which is coated by means of vacuum-plasma sputtering has improved adhesion to a metallic surface due to the high-energy coating process providing covalent and ionic bondings between a material to be coated and plasma-spattered coating.
- Negative charge of the electret film can be temporally stable for a predetermined period of time. It is known in the art that the time characteristic can be varied by means of changes in the technological process.
- the tantalum pentoxide coating is characterized by essential radiopacity.
- At least one wire member is coated with tantalum pentoxide, and then the obtained coated wire member(s) is configured into a stent expandable due to plastic deformation.
- tantalum pentoxide coating result in local occurrence of positive electric potentials.
- the blood cells which are aggregated in thrombosis are negatively charged.
- discontinuances in coating integrality will be centers of clottage/thrombosis.
- the coating process of the entire stent is very problematic. Specifically, adhesion of the coating in intertangling areas is much lower than the adhesion at linear areas.
- wire member is configured into the celled structure after coating with tantalum pentoxide.
- adhesion value does not depend on a position on the stent and has a constant value in any location on the stent.
- positive potential does not occur in any location.
- the entire stent is negatively charged and prevents any clottage/thrombosis thereon.
- the negatively charged stent can be made of a number of wire members which are coated with tantalum pentoxide before. In this case, impermeability of the coating is not broken, and the positive charge does not occur at the stent surface, because coating integrality of each wire member is kept during a process of stent fabrication.
- Figs 1 a to Id illustrating general views of commercially available stents. Specifically, Fig. la and Fig. lb show wire wound stents. Figs lc and Fig. Id illustrate a braided stent and a mesh-like stent laser cut of a tube, respectively.
- Fig. 2a presenting an exemplar mesh-like structure made by means of laser cutting.
- Numerals 10 and 20 refer to a wire element and a node, respectively.
- locations 30 and similar having the mesh elements 10 meeting together at the node 20 at an acute angle serve as points of clot formation.
- Fig. 2b showing an exemplar mesh-like structure made of wavelike wire elements 40 which are secured to each other by means of spot welding 50.
- the locations 30 can be characterized as dangerous in terms of clot formation.
- FIG. 2c presenting an exemplar mesh constituting an interlaced wire structure.
- Wires 60 are interlaced in locations 70 which are points of clot formation.
- a numeral 80 refers to a cross-sectional view of the interlaced wires 60.
- Fig. 3a is an illustration specifying aggregation of blood particles into a clot. Specifically, thrombocytes 90 aggregate in proximity of interlaced wires and form a clot.
- Fig. 3b showing claimed prevention of the thrombocytes from aggregation in proximity of dangerous locations.
- the thrombocytes carry negative electric charge.
- An electret coating also carries a permanent negative charge and repels the thrombocytes from the dangerous locations and hence prevents the thrombocytes from aggregation in proximity of the stent.
- Equipotential lines 100 characterize electric field intensity in proximity of the interlaced wires.
- a direction of a repelling force acting onto the thrombocytes 90 is indicated by a numeral 1 10.
- the method of manufacturing the claimed article comprises a step of expanding the article to be coated to prevent shaded areas to provide an integral surface blanketing an entire surface of said wire member.
- the expanded stent is mounted on a massive base plate providing effective heat sinking to prevent the stent to be coated from overheating during the coating process.
- a distance between two neighboring wires is less 15 wire diameters.
- the described stent arrangement provides substantially uniform electrostatic field preventing blood cells from aggregation on the stent wires.
- an article insertable into a patient's body
- a core feature is to provide the article coated with a coating having an electret structure.
- the article is selected from the group consisting of a vascular stent, an artificial cardiac valve, a suture material, orthopedic article, applicator, hernia mesh, an acupuncture needle including corporeal needle, otic needle, long-term needle, ball, plate, and any combination thereof.
- a vascular stent carrying a surface negative charge comprises at least one metal wire member configured into a cylindrical celled frame.
- Another core feature is to provide the wire member coated with a coating having an electret structure.
- the coating has an integral surface blanketing an entire surface of said wire member.
- the vascular stent is constructed of tubing cut into a mesh shape.
- the vascular stent is constructed of at least one wire into a mesh shape.
- the coating is tantalum pentoxide.
- the tantalum pentoxide coating is vacuum-plasma sputtering.
- a further object of the invention is to disclose the said coating is Polytetrafluoroethylene.
- a method of manufacturing an article carrying a negative charge and insertable into a patient's body comprises the steps of: (a) providing an article work piece; and (b) coating said work piece with a coating carrying a negative charge.
- the step of coating said wire members further comprises creating an integral surface blanketing an entire surface of said wire member.
- the step of coating said wire members further comprises sputtering tantalum pentoxide.
- the step of sputtering tantalum pentoxide is performed by means of vacuum-plasma sputtering.
Abstract
Description
Claims
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201380007031.3A CN104093431A (en) | 2012-01-30 | 2013-01-28 | Negatively charged vascular stent |
RU2014135198A RU2014135198A (en) | 2012-01-30 | 2013-01-28 | Negatively charged vascular stent |
JP2014553857A JP2015513301A (en) | 2012-01-30 | 2013-01-28 | Negatively charged vascular stent |
US14/375,435 US20140379069A1 (en) | 2012-01-30 | 2013-01-28 | Negatively charged vascular stent |
EP13744401.4A EP2809370B1 (en) | 2012-01-30 | 2013-01-28 | Negatively charged vascular stent |
IL233718A IL233718A0 (en) | 2012-01-30 | 2014-07-20 | Negatively charged vascular stent |
US15/650,925 US20170312504A1 (en) | 2012-01-30 | 2017-07-16 | Implant for use in the cardiovascular system |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261592013P | 2012-01-30 | 2012-01-30 | |
US61/592,013 | 2012-01-30 | ||
US201261674861P | 2012-07-24 | 2012-07-24 | |
US61/674,861 | 2012-07-24 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/375,435 A-371-Of-International US20140379069A1 (en) | 2012-01-30 | 2013-01-28 | Negatively charged vascular stent |
US15/650,925 Continuation-In-Part US20170312504A1 (en) | 2012-01-30 | 2017-07-16 | Implant for use in the cardiovascular system |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2013114358A1 true WO2013114358A1 (en) | 2013-08-08 |
WO2013114358A9 WO2013114358A9 (en) | 2013-12-27 |
Family
ID=48904503
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IL2013/050074 WO2013114358A1 (en) | 2012-01-30 | 2013-01-28 | Negatively charged vascular stent |
Country Status (6)
Country | Link |
---|---|
US (1) | US20140379069A1 (en) |
EP (1) | EP2809370B1 (en) |
JP (1) | JP2015513301A (en) |
CN (1) | CN104093431A (en) |
RU (1) | RU2014135198A (en) |
WO (1) | WO2013114358A1 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108136203A (en) * | 2015-08-17 | 2018-06-08 | 波士顿科学国际有限公司 | Radiant stand |
Citations (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996041589A1 (en) | 1995-06-13 | 1996-12-27 | William Cook Europe A/S | A device for implantation in a vessel or hollow organ lumen |
US5759205A (en) * | 1994-01-21 | 1998-06-02 | Brown University Research Foundation | Negatively charged polymeric electret implant |
US6231600B1 (en) | 1995-02-22 | 2001-05-15 | Scimed Life Systems, Inc. | Stents with hybrid coating for medical devices |
US20060106451A1 (en) | 2004-11-18 | 2006-05-18 | Yuri Busiashvili | Electronic anti-coagulation stent for intra-arterial deployment |
US20080140187A1 (en) * | 2004-10-15 | 2008-06-12 | Krause Arthur A | Anti-clotting, anti-microbial, anti-inflammatory medical stent |
US20080208315A1 (en) | 2007-02-27 | 2008-08-28 | National Taiwan University Of Science & Technology | Coronary stent having a surface of multi-layer immobilized structures |
US20090211076A1 (en) * | 2008-02-27 | 2009-08-27 | C. R. Bard, Inc. | Stent-graft covering process |
RU2380059C1 (en) | 2008-08-19 | 2010-01-27 | Екатерина Игоревна Шишацкая | Stent coating |
WO2011094459A1 (en) * | 2010-01-27 | 2011-08-04 | Iyer Sriram S | Device and method for preventing stenosis at an anastomosis site |
US20110196478A1 (en) | 2010-02-10 | 2011-08-11 | Beoptima Inc. | Devices and methods for lumen treatment |
WO2011109447A1 (en) * | 2010-03-02 | 2011-09-09 | University Of Rochester | Implantable devices that generate low intensity electric fields for the treatment of atherosclerotic disease and prevention of ischemic vascular events and methods of manufacture |
WO2011156603A2 (en) * | 2010-06-09 | 2011-12-15 | Semprus Biosciences Corp. | Articles having non-fouling surfaces and processes for preparing the same without altering bulk physical properties |
RU2446775C2 (en) | 2006-06-20 | 2012-04-10 | Рева Медикал, Инк. | Stent from sliding and blocking elements |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5078736A (en) * | 1990-05-04 | 1992-01-07 | Interventional Thermodynamics, Inc. | Method and apparatus for maintaining patency in the body passages |
CA2308396A1 (en) * | 1997-05-14 | 1998-11-19 | Novo Rps Ulc | Expandable stent and method for production of same |
US6685734B1 (en) * | 1999-12-17 | 2004-02-03 | Linvatec Biomaterials Oy | Urethral stent delivery system |
WO2002024249A2 (en) * | 2000-09-22 | 2002-03-28 | Koole Levinas H | Method for immobilizing poly(hema) on stents |
DE10322182A1 (en) * | 2003-05-16 | 2004-12-02 | Blue Membranes Gmbh | Process for the production of porous, carbon-based material |
US20050165472A1 (en) * | 2004-01-22 | 2005-07-28 | Glocker David A. | Radiopaque coating for biomedical devices |
US20090177273A1 (en) * | 2006-05-17 | 2009-07-09 | Laurent-Dominique Piveteau | Anisotropic nanoporous coatings for medical implants |
US20090171451A1 (en) * | 2007-12-27 | 2009-07-02 | Cook Incorporated | Implantable device having composite weave |
US8992761B2 (en) * | 2012-07-13 | 2015-03-31 | Abbott Cardiovascular Systems, Inc. | Methods for passivating metallic implantable medical devices including radiopaque markers |
-
2013
- 2013-01-28 JP JP2014553857A patent/JP2015513301A/en active Pending
- 2013-01-28 WO PCT/IL2013/050074 patent/WO2013114358A1/en active Application Filing
- 2013-01-28 CN CN201380007031.3A patent/CN104093431A/en active Pending
- 2013-01-28 US US14/375,435 patent/US20140379069A1/en not_active Abandoned
- 2013-01-28 RU RU2014135198A patent/RU2014135198A/en not_active Application Discontinuation
- 2013-01-28 EP EP13744401.4A patent/EP2809370B1/en active Active
Patent Citations (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5759205A (en) * | 1994-01-21 | 1998-06-02 | Brown University Research Foundation | Negatively charged polymeric electret implant |
US6231600B1 (en) | 1995-02-22 | 2001-05-15 | Scimed Life Systems, Inc. | Stents with hybrid coating for medical devices |
WO1996041589A1 (en) | 1995-06-13 | 1996-12-27 | William Cook Europe A/S | A device for implantation in a vessel or hollow organ lumen |
US20080140187A1 (en) * | 2004-10-15 | 2008-06-12 | Krause Arthur A | Anti-clotting, anti-microbial, anti-inflammatory medical stent |
US20060106451A1 (en) | 2004-11-18 | 2006-05-18 | Yuri Busiashvili | Electronic anti-coagulation stent for intra-arterial deployment |
RU2446775C2 (en) | 2006-06-20 | 2012-04-10 | Рева Медикал, Инк. | Stent from sliding and blocking elements |
US20080208315A1 (en) | 2007-02-27 | 2008-08-28 | National Taiwan University Of Science & Technology | Coronary stent having a surface of multi-layer immobilized structures |
US20090211076A1 (en) * | 2008-02-27 | 2009-08-27 | C. R. Bard, Inc. | Stent-graft covering process |
RU2380059C1 (en) | 2008-08-19 | 2010-01-27 | Екатерина Игоревна Шишацкая | Stent coating |
WO2011094459A1 (en) * | 2010-01-27 | 2011-08-04 | Iyer Sriram S | Device and method for preventing stenosis at an anastomosis site |
US20110196478A1 (en) | 2010-02-10 | 2011-08-11 | Beoptima Inc. | Devices and methods for lumen treatment |
WO2011109447A1 (en) * | 2010-03-02 | 2011-09-09 | University Of Rochester | Implantable devices that generate low intensity electric fields for the treatment of atherosclerotic disease and prevention of ischemic vascular events and methods of manufacture |
WO2011156603A2 (en) * | 2010-06-09 | 2011-12-15 | Semprus Biosciences Corp. | Articles having non-fouling surfaces and processes for preparing the same without altering bulk physical properties |
Non-Patent Citations (1)
Title |
---|
See also references of EP2809370A4 |
Also Published As
Publication number | Publication date |
---|---|
JP2015513301A (en) | 2015-05-07 |
CN104093431A (en) | 2014-10-08 |
EP2809370A1 (en) | 2014-12-10 |
EP2809370B1 (en) | 2020-08-26 |
RU2014135198A (en) | 2016-03-27 |
US20140379069A1 (en) | 2014-12-25 |
WO2013114358A9 (en) | 2013-12-27 |
EP2809370A4 (en) | 2015-09-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11523919B2 (en) | Stent | |
US6652581B1 (en) | Medical device with porous surface for controlled drug release and method of making the same | |
EP1460972B1 (en) | Layered stent-graft and methods of making the same | |
JP5102029B2 (en) | Metallic drug release medical device and method for producing the same | |
US9907682B2 (en) | Implantable prosthesis with radiopaque particles and method of making same | |
US20060265049A1 (en) | Stent and MR imaging process and device | |
US10632004B2 (en) | Hollow drug-filled stent and method of forming hollow drug-filled stent | |
WO2008005524A1 (en) | Stent with a radiopaque marker and method for making the same | |
AU2018264124B2 (en) | Monolithic medical device, methods of making and using the same | |
EP4088756A1 (en) | Medical device for use in human vessels having a fibrin coating including fibronectin | |
EP2809370B1 (en) | Negatively charged vascular stent | |
CN109922760B (en) | Drug-filled stent for preventing vascular micro-injury and manufacturing method thereof | |
JP2002355316A (en) | Stent cover and stent | |
US20170312504A1 (en) | Implant for use in the cardiovascular system | |
JPWO2004080521A1 (en) | Stent | |
US9149375B2 (en) | Radiopaque drug-filled prosthesis and method of making same | |
US20230293774A1 (en) | Stent graft with elastomeric impermeable layer | |
CA2579524A1 (en) | Medical device with porous surface for controlled drug release and method of making the same | |
MX2007000912A (en) | Metallic drug-releasing medical devices and method of making same |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 13744401 Country of ref document: EP Kind code of ref document: A1 |
|
DPE1 | Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 233718 Country of ref document: IL |
|
ENP | Entry into the national phase |
Ref document number: 2014553857 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 14375435 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2013744401 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2014135198 Country of ref document: RU |